Last reviewed · How we verify

NCT04971213

HIgh Flow Versus NIV for Acute Cardiogenic PuLmonary Oedema With Acute Respiratory Failure in an ED

Completed NA Last updated 6 January 2023
What this trial tests

NA trial testing Non invasive ventilation in Cardiogenic Pulmonary Edema in 60 participants. Completed in 1 December 2022.

Timeline
22 September 2021
Primary endpoint
1 November 2022
1 December 2022

Quick facts

Lead sponsorPoitiers University Hospital
PhaseNA
StatusCompleted
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingnone
Primary purposetreatment
Enrollment60
Start date22 September 2021
Primary completion1 November 2022
Estimated completion1 December 2022
Sites1 location across France

Drugs / interventions tested

Conditions studied

Sponsor

Poitiers University Hospital

Who can join

Adults 18 to 100, any sex, with Cardiogenic Pulmonary Edema. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this study is to compare non invasive ventilation to high flow nasal cannula oxygen for the management of patients admitted with an acute respiratory failure due to an acute cardiogenic pulmonary edema.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

  1. High-flow nasal cannula oxygen versus noninvasive ventilation for the management of acute cardiogenic pulmonary edema: a randomized controlled pilot study.
    Marjanovic N, Piton M, Lamarre J, Alleyrat C, et al · · 2024 · cited 12× · PMID 38364020 · DOI 10.1097/mej.0000000000001128

Verify or expand the search:

Other trials of Non invasive ventilation

Trials testing the same drug.

Other Poitiers University Hospital trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04971213.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing